First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform

New Color-Coded Embolic with Polyzene(R)-F Coating Enhances Procedural Safety, Efficiency during Treatment of Hypervascularized Tumors and Arteriovenous Malformations
NEWNAN, Ga., Dec. 31 (HSMN NewsFeed) -- Against the backdrop of a flagging economy, bailouts, and bleak predictions, there is a biotechnology firm in suburban Atlanta with a future as bright as New Year's Eve fireworks. Only days after receiving FDA approval to market the Embozene(TM) Color-Advanced Microspheres embolization platform for the treatment of hypervascularized tumors (tumors with a large number of blood vessels in many locations) and arteriovenous malformations (defects in the circulatory system), CeloNova BioSciences today announced that the product has been successfully used to treat several patients at two Atlanta area hospitals: Emory-Adventist Hospital in Smyrna and WellStar Windy Hill Hospital in Marietta.
Dr. John Lipman, who performed the procedures at both hospitals, said, "I was really impressed with the Embozene(TM) Color-Advanced Microspheres. The material handled well, going immediately into suspension and, importantly, staying in suspension. The fact that Embozene(TM) Microspheres are color coded to size is an appealing feature that allows good visibility of the material and clearly creates a higher and important safety profile. CeloNova has apparently carefully engineered these beads to be extremely 'friendly' for the physician to use. I found in these first patients that the product was highly manageable during the procedure. I achieved the procedural goals to devascularize the tumors quickly, using much less material than other products, having far less radiation time for the patient, and requiring less contrast media. These are all important and present features."

Full article >> http://salesandmarketingnetwork.com/news_release.php?pipe=0000ac177000191&ID=2026832